PlainPharmaWatch

CMS Open Payments · Program Year 2024

Orexo US, Inc.

Orexo US, Inc. reported $36,312.83 across General Payments, Research, and Ownership to 2,075 physicians and teaching hospitals across 2,075 transactions.

See the rankings → How this is sourced
$36.3K
All-tracks total
2,075
Transactions
2,075
Recipients
+$691.00
General Payments vs PY2023

Orexo US, Inc. reported $36,312.83 across all CMS Open Payments tracks (General + Research + Ownership) to 2,075 physicians and teaching hospitals in Program Year 2024 - ranking #1427 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $36,312.83, averaging $17.50 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer orexo-us-inc Orexo US, Inc.

$36.3K · #1427/1,925 · 0.0% industry · PY2024

  • TOT $36.3K
  • RANK #1427
  • SHARE 0.0%
  • TXN 2,075
  • RCP 2,075
  • CAT 1
  • GEN $36.3K
  • ΔGEN +$691.00
  • TOP1 0.7%
  • PY 2024

Volume peers

Nearest volume peer: D.T. Davis Enterprises, Ltd ($36.4K)

Mauna Kea Technologies, Inc.$36.6KClinical Technology, Inc$36.5KD.T. Davis Enterprises, Ltd$36.4KOrexo US, Inc. (this)$36.3KDiagnostic Green GmbH$36.0K
All-tracks payment totals near Orexo US, Inc. (CMS Open Payments PY2024)

Orexo US, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Orexo US, Inc.'s CMS-reported General Payments increased by $691.00 (+1.9%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: OREXO US, INC.PY2023: OREXO US, INC.PY2024: Orexo US, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$35.6KPY2024$36.3K
PY2023
$35,621.83
PY2024
$36,312.83

What the Data Shows for Orexo US, Inc.

Orexo US, Inc. ranks #1427 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $36,312.83 across 2,075 transactions to 2,075 physicians and teaching hospitals - $17.50 per transaction and $17.50 per recipient on average.

The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $36.3K, accounting for 100.0% of this company's General Payments and 2,075 transactions.

General Payment Breakdown by Type

Across 1 types of general payments, Orexo US, Inc.'s largest category was "Food and Beverage" at $36.3K - 100.0% of General Payments.

How Orexo US, Inc. divides its payments

Ranked by total dollars reported per category

1. Food and Beverage$36.3K
Payment Type Amount Transactions
Food and Beverage $36.3K 2,075

Recipient Concentration in General Payments

The five largest recipient relationships account for $1,165.61 (3.2%) of $36,312.83 in this company's General Payments records across 929 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Orexo US, Inc.

The five named recipients with the highest reported General Payments from this company

Michael Royall$261.68Laurence Fox$237.42Jeff Summe$231.47Justin Harricharran$220.22Michelle Gomez$214.82
  1. 1

    Michael Royall

    $261.68 across 18 reported transactions

  2. 2

    Laurence Fox

    $237.42 across 16 reported transactions

  3. 3

    Jeff Summe

    $231.47 across 11 reported transactions

  4. 4

    Justin Harricharran

    $220.22 across 17 reported transactions

  5. 5

    Michelle Gomez

    $214.82 across 19 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Orexo US, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Orexo US, Inc..

Genentech USA, Inc.

HHI 20

Seagen Inc.

HHI 20

Valinor Pharma, LLC

HHI 20

Pfizer Inc.

HHI 22

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Orexo US, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Orexo US, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.